| scholarly article | Q13442814 |
| P50 | author | Gerd Geerling | Q15280969 |
| Christophe Baudouin | Q37616711 | ||
| Margarita Calonge | Q43119624 | ||
| Kostas G Boboridis | Q52349976 | ||
| Maurizio Rolando | Q59378397 | ||
| P2093 | author name string | Marc Labetoulle | |
| Pasquale Aragona | |||
| Yonca A Akova | |||
| Alan Tomlinson | |||
| Elisabeth M Messmer | |||
| P433 | issue | 4 | |
| P921 | main subject | pathogenesis | Q372016 |
| eye disease | Q3041498 | ||
| P304 | page(s) | 246-258 | |
| P577 | publication date | 2013-08-09 | |
| P1433 | published in | The Ocular Surface | Q15764153 |
| P1476 | title | Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting | |
| P478 | volume | 11 |
| Q64072411 | A Phase I/II Placebo-Controlled Randomized Pilot Clinical Trial of Recombinant Deoxyribonuclease (DNase) Eye Drops Use in Patients With Dry Eye Disease |
| Q36887538 | A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease |
| Q33800709 | A prospective, multicenter, noninterventional study of Optive Plus(®) in the treatment of patients with dry eye: the prolipid study |
| Q54222666 | A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. |
| Q91639178 | Acupoint selection for the treatment of dry eye: A systematic review and meta-analysis of randomized controlled trials |
| Q64246027 | Air Pollutants are associated with Dry Eye Disease in Urban Ophthalmic Outpatients: a Prevalence Study in China |
| Q38207723 | An update on dry eye disease molecular treatment: advances in drug pipelines |
| Q53081062 | Anti-Inflammatory and Anti-Apoptotic Effects of Acer Palmatum Thumb. Extract, KIOM-2015EW, in a Hyperosmolar-Stress-Induced In Vitro Dry Eye Model. |
| Q89539996 | Aqueous deficiency is a contributor to evaporation-related dry eye disease |
| Q90746682 | Changes in Corneal Detection Thresholds After Repeated Tear Film Instability |
| Q38733230 | Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting |
| Q52643805 | Combination of hyaluronic acid, carmellose, and osmoprotectants for the treatment of dry eye disease. |
| Q38820903 | Comparison of 0.3% Hypotonic and Isotonic Sodium Hyaluronate Eye Drops in the Treatment of Experimental Dry Eye. |
| Q36656777 | Comparison of the Anti-Inflammatory Effects of Artificial Tears in a Rat Model of Corneal Scraping |
| Q33572910 | Computed tear film and osmolarity dynamics on an eye-shaped domain |
| Q58122088 | Conjunctival Inflammatory Gene Expression Profiling in Dry Eye Disease: Correlations With HLA-DRA and HLA-DRB1 |
| Q92073703 | Corneal alteration and pathogenesis in diabetes mellitus |
| Q38810021 | Desiccating stress-induced disruption of ocular surface immune tolerance drives dry eye disease. |
| Q34092386 | Diagnosing the severity of dry eye: a clear and practical algorithm |
| Q34144866 | Discrepancy between subjectively reported symptoms and objectively measured clinical findings in dry eye: a population based analysis |
| Q90451538 | Disease aetiology-based design of multifunctional microemulsion eye drops for moderate or severe dry eye: a randomized, quadruple-masked and active-controlled clinical trial |
| Q47639135 | Dry eye syndrome: developments and lifitegrast in perspective |
| Q36038395 | Dual-Polymer Drops, Contact Lens Comfort, and Lid Wiper Epitheliopathy |
| Q35190697 | Dynamics and function of the tear film in relation to the blink cycle |
| Q36323797 | Edaravone protects against hyperosmolarity-induced oxidative stress and apoptosis in primary human corneal epithelial cells |
| Q58702689 | Effect of 5-Oxo-2-Pyrrolidinecarboxylic Acid (PCA) as a New Topically Applied Agent for Dry Eye Syndrome Treatment |
| Q58805766 | Effect of Hyaluronic Acid/Trehalose in Two Different Formulations on Signs and Symptoms in Patients with Moderate to Severe Dry Eye Disease |
| Q48143565 | Effect of different lubricant eye gels on tear film thickness as measured with ultrahigh-resolution optical coherence tomography |
| Q36292520 | Effects of 3% trehalose as an adjuvant treatment after LASIK. |
| Q88073084 | Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies |
| Q35507058 | Efficacy and safety of two new formulations of artificial tears in subjects with dry eye disease: a 3-month, multicenter, active-controlled, randomized trial |
| Q38905054 | External eye symptoms in indoor environments |
| Q34677680 | Hyperosmolar stress induces neutrophil extracellular trap formation: implications for dry eye disease |
| Q42265323 | Hyperosmotic stress induces ATP release and changes in P2X7 receptor levels in human corneal and conjunctival epithelial cells. |
| Q49924138 | Impact of Smoking on the Ocular Surface, Tear Function, and Tear Osmolarity. |
| Q36093656 | In Vitro Inhibition of NFAT5-Mediated Induction of CCL2 in Hyperosmotic Conditions by Cyclosporine and Dexamethasone on Human HeLa-Modified Conjunctiva-Derived Cells |
| Q35843885 | In Vivo and Impression Cytology Study on the Effect of Compatible Solutes Eye Drops on the Ocular Surface Epithelial Cell Quality in Dry Eye Patients |
| Q47139729 | In vivo imaging of palisades of Vogt in dry eye versus normal subjects using en-face spectral-domain optical coherence tomography |
| Q42503008 | Increased corneal sub-basal nerve density in patients with Sjögren syndrome treated with topical cyclosporine A. |
| Q95840976 | Intravital Multiphoton Microscopy of the Ocular Surface: Alterations in Conventional Dendritic Cell Morphology and Kinetics in Dry Eye Disease |
| Q53534950 | Keratitis in Dry Eye Disease and Topical Ciclosporin A. |
| Q53818675 | Management of post-LASIK dry eye: a multicenter randomized comparison of a new multi-ingredient artificial tear to carboxymethylcellulose. |
| Q41493127 | Meibomian gland features in a Norwegian cohort of patients with primary Sjögren´s syndrome |
| Q47442388 | Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation. |
| Q39097223 | Mucosal immune tolerance at the ocular surface in health and disease |
| Q57383056 | Novel Nano-Liposome Formulation for Dry Eyes with Components Similar to the Preocular Tear Film |
| Q28068115 | Ocular surface mucins and local inflammation--studies in genetically modified mouse lines |
| Q42506915 | Omega-3 supplementation is neuroprotective to corneal nerves in dry eye disease: a pilot study. |
| Q47916097 | On tear film breakup (TBU): dynamics and imaging |
| Q53836361 | One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease. |
| Q34193277 | Osmoprotectants suppress the production and activity of matrix metalloproteinases induced by hyperosmolarity in primary human corneal epithelial cells. |
| Q42702543 | Osmoprotectants, carboxymethylcellulose and hyaluronic acid multi-ingredient eye drop: a randomised controlled trial in moderate to severe dry eye. |
| Q35646417 | Oxidative stress markers induced by hyperosmolarity in primary human corneal epithelial cells |
| Q34829096 | Potentially pathogenic immune cells and networks in apparently healthy lacrimal glands |
| Q91905513 | Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease |
| Q33829987 | Prednisolone induces apoptosis in corneal epithelial cells through the intrinsic pathway |
| Q47381165 | Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages. |
| Q35979980 | Protective Effects of L-Carnitine Against Oxidative Injury by Hyperosmolarity in Human Corneal Epithelial Cells |
| Q42324571 | Protein Kinase R Mediates the Inflammatory Response Induced by Hyperosmotic Stress |
| Q52889830 | Randomized Controlled Crossover Trial Comparing the Impact of Sham or Intranasal Tear Neurostimulation on Conjunctival Goblet Cell Degranulation. |
| Q26771284 | Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction |
| Q35472653 | Sensitization of trigeminal brainstem pathways in a model for tear deficient dry eye |
| Q47138569 | TRI Microspheres prevent key signs of dry eye disease in a murine, inflammatory model. |
| Q55005003 | Tear osmolarity changes after use of hydroxypropyl-guar-based lubricating eye drops. |
| Q47112214 | Tear proteome analysis in ocular surface diseases using label-free LC-MS/MS and multiplexed-microarray biomarker validation |
| Q36811289 | The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy |
| Q38750436 | The Blockade of IL6 Counterparts the Osmolar Stress-Induced Apoptosis in Human Conjunctival Epithelial Cells. |
| Q39233384 | The correct diagnosis and therapeutic management of tear dysfunction: recommendations of the P.I.C.A.S.S.O. board |
| Q41484441 | The effect of intravitreal injections on dry eye, and proposed management strategies |
| Q38270449 | The role and treatment of inflammation in dry eye disease |
| Q50025206 | Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program. |
| Q59812970 | Vascular Endothelial Growth Factor (VEGF) Induced Downstream Responses to Transient Receptor Potential Vanilloid 1 (TRPV1) and 3-Iodothyronamine (3-TAM) in Human Corneal Keratocytes |
| Q48027974 | Vitamin D Replacement Improves Tear Osmolarity in Patients with Vitamin D Deficiency |
Search more.